Related Experiment Video
Updated: Aug 17, 2026
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
Published on: July 23, 2016
The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization
A N Antoszyk1, J L Gottlieb, R Machemer
1Department of Ophthalmology, Duke University, Durham, N.C.
Abstract:
Corticosteroids, alone or in combination with other drugs, have been shown to inhibit angiogenesis. The purpose of this study was to evaluate the efficacy of triamcinolone acetonide in a new model of preretinal neovascularization. Rabbit eyes were treated with intravitreal triamcinolone acetonide 24 h before partial liquefaction of the posterior vitreous with hyaluronidase and injection of 250,000 homologous tissue-cultured dermal fibroblasts. Triamcinolone acetonide effectively inhibited new vessel growth in treated eyes. Only 14% of the treated eyes developed new blood vessels compared to 100% of sham-injected control eyes (P < 0.001). These results suggest that intravitreal triamcinolone acetonide might be effective in inhibiting new vessel growth in patients with inflammatory retinal neovascularization, such as that associated with sarcoidosis or other uveitic syndromes.
Insights
Triamcinolone acetonide effectively inhibited preretinal neovascularization in a rabbit model. This corticosteroid shows promise for treating inflammatory retinal neovascularization in conditions like uveitis.
Area of Science:
- Ophthalmology
- Vascular Biology
- Pharmacology
Background:
- Corticosteroids are known to inhibit angiogenesis.
- Inflammatory retinal neovascularization is a significant cause of vision loss.
- New therapeutic models are needed to study and treat this condition.
Purpose of the Study:
- To evaluate the efficacy of triamcinolone acetonide in a novel preretinal neovascularization model.
- To assess the anti-angiogenic potential of intravitreal triamcinolone acetonide.
Main Methods:
- A rabbit eye model was established involving vitreous liquefaction and fibroblast injection.
- Eyes received intravitreal triamcinolone acetonide 24 hours prior to the procedure.
- Neovascularization was assessed in treated and sham-injected control eyes.
Main Results:
- Intravitreal triamcinolone acetonide significantly inhibited new blood vessel growth.
- Only 14% of treated eyes showed neovascularization compared to 100% in controls (P < 0.001).
Conclusions:
- Intravitreal triamcinolone acetonide demonstrated potent inhibition of experimental preretinal neovascularization.
- This finding suggests potential therapeutic applications for inflammatory retinal neovascularization, including uveitic syndromes.
